Free Trade or Freebies for the Powerful?

As the United States Congress begins to debate the Dominican Republic-Central American Free Trade Agreement (DR-CAFTA), a titanic struggle between the forces of free trade and protectionism promises to unfold. But that debate should not be allowed to mask the truth behind this treaty: the DR-CAFTA is more a pleading of special interests than a free-trade deal. It manages simultaneously to fleece the people of six poor countries and to put US workers in harm’s way.

To be sure, expanded trade holds great promise for promoting development and democracy. But the trade rules inscribed in DR-CAFTA promote profits for a few at the expense of the well being of the many. Ironically, the pact even limits market competition to protect powerful special interests, undercutting the core principles of free trade.

Consider pharmaceuticals. For American drug companies, this agreement extends the time period during which brand-name pharmaceuticals have exclusive access to markets, postponing the entry of generic drugs and thus limiting competition. For Central Americans, the cost of drugs will soar, straining budgets and gutting health care. The result may be a death sentence for many.

To continue reading, please log in or enter your email address.

To continue reading, please log in or register now. After entering your email, you'll have access to two free articles every month. For unlimited access to Project Syndicate, subscribe now.


By proceeding, you are agreeing to our Terms and Conditions.

Log in;

Cookies and Privacy

We use cookies to improve your experience on our website. To find out more, read our updated cookie policy and privacy policy.